Table 2.

Summary of adverse events in patients with MSS mCRC

Adverse events (AE)	Favezelimab N = 20		Favezelimab + pembrolizumab N = 89a
Any AE	19 (95.0)		87 (97.8)
Any treatment-related AE	13 (65.0)		58 (65.2)
Grade 3-4	3 (15.0)		18 (20.2)
Led to discontinuation	0		5 (5.6)
Immune-mediated AEs	2 (10.0)		32 (36.0)
Events ≥5% in any armb	Any grade	Grade ≥3	Any grade	Grade ≥3
Nausea	3 (15.0)	0	4 (4.5)	0
Fatigue	4 (20.0)	1 (5.0)	15 (16.9)	2 (2.2)
Influenza-like illness	2 (10.0)	0	0	0
Hypothyroidism	1 (5.0)	0	13 (14.6)	0
Diarrhea	1 (5.0)	0	3 (3.4)	0
Vomiting	1 (5.0)	0	1 (1.1)	0
Pruritus	1 (5.0)	0	7 (7.9)	0
Maculopapular rash	1 (5.0)	0	6 (6.7)	1 (1)
Rash	1 (5.0)	0	5 (5.6)	0
Lipase increased	1 (5.0)	1 (5.0)	0	0
Thyroid function test abnormal	1 (5.0)	0	0	0
Syncope	1 (5.0)	1 (5.0)	0	0
Arthralgia	1 (5.0)	0	2 (2.2)	0
Back pain	1 (5.0)	0	1 (1.1)	0
Muscle tightness	1 (5.0)	0	0	0
Chills	1 (5.0)	0	2 (2.2)	0
Infusion-related reaction	1 (5.0)	0	6 (6.7)	1 (1.1)
ALT increased	1 (5.0)	0	3 (3.4)	2 (2.2)
Hyperphosphatemia	1 (5.0)	0	0	0
Cough	1 (5.0)	0	4 (4.5)	0
Dermatitis acneiform	1 (5.0)	0	0	0
Photosensitivity reaction	1 (5.0)	0	0	0
Pneumonitis	0	0	5 (5.6)	2 (2.2)
Hyperthyroidism	0	0	5 (5.6)	0

There were no grade 5 treatment-related events.

ALT, alanine aminotransferase; mCRC, metastatic colorectal cancer; MSS, microsatellite stable.

^aIncludes nine patients who crossed over from favezelimab monotherapy.

^bTreatment-related adverse events.